Teva Fights To Invalidate Astellas' Urinary Drug Patent
Teva has urged a London court to invalidate a U.K. patent held by Astellas for a urinary incontinence drug because it allegedly involves an obvious scientific formula, as the generic drug...To view the full article, register now.
Already a subscriber? Click here to view full article